Clene Inc. to Present at D. Boral Capital Global Conference, Showcasing Neurodegenerative Disease Research

Clene Inc., a biopharmaceutical company specializing in neurodegenerative disease research, will present at the D. Boral Capital Inaugural Global Conference in New York City. President and CEO Rob Etherington is scheduled to participate in one-on-one meetings, providing an opportunity for investors and analysts to gain deeper understanding of the company's groundbreaking work.

The conference, taking place at The Plaza Hotel, will allow Clene to showcase its innovative approach to treating neurological conditions such as amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. The company's primary focus is on improving mitochondrial health and protecting neuronal function through its investigational therapy CNM-Au8®.

CNM-Au8® represents a potentially significant advancement in neurological treatment, targeting mitochondrial function and the NAD pathway while simultaneously reducing oxidative stress. This unique mechanism could offer new hope for patients suffering from challenging neurodegenerative diseases that currently have limited treatment options.

By participating in this conference, Clene provides an important platform to communicate its scientific research and potential therapeutic developments to key stakeholders in the medical and investment communities. The one-on-one meeting format allows for detailed discussions about the company's research strategies, clinical trial progress, and potential future breakthroughs.

Located in Salt Lake City, Utah, with research and development operations in Maryland, Clene continues to position itself at the forefront of neurological disease research. The upcoming conference represents an critical opportunity for the company to demonstrate its commitment to developing innovative treatments that could potentially transform patient care in neurodegenerative conditions.